IS2186B - Ísómerísk sambrædd pýrrólókarbasól og ísóindólón - Google Patents

Ísómerísk sambrædd pýrrólókarbasól og ísóindólón

Info

Publication number
IS2186B
IS2186B IS6266A IS6266A IS2186B IS 2186 B IS2186 B IS 2186B IS 6266 A IS6266 A IS 6266A IS 6266 A IS6266 A IS 6266A IS 2186 B IS2186 B IS 2186B
Authority
IS
Iceland
Prior art keywords
isoindolone
fused pyrrolocarbazole
isomeric fused
directed
same
Prior art date
Application number
IS6266A
Other languages
English (en)
Other versions
IS6266A (is
Inventor
L. Hudkins Robert
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of IS6266A publication Critical patent/IS6266A/is
Publication of IS2186B publication Critical patent/IS2186B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IS6266A 1999-08-20 2002-02-12 Ísómerísk sambrædd pýrrólókarbasól og ísóindólón IS2186B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15036799P 1999-08-20 1999-08-20
US09/640,825 US6399780B1 (en) 1999-08-20 2000-08-17 Isomeric fused pyrrolocarbazoles and isoindolones
PCT/US2000/022724 WO2001014380A1 (en) 1999-08-20 2000-08-18 Isomeric fused pyrrolocarbazoles and isoindolones

Publications (2)

Publication Number Publication Date
IS6266A IS6266A (is) 2002-02-12
IS2186B true IS2186B (is) 2006-12-15

Family

ID=26847579

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6266A IS2186B (is) 1999-08-20 2002-02-12 Ísómerísk sambrædd pýrrólókarbasól og ísóindólón

Country Status (26)

Country Link
US (4) US6399780B1 (is)
EP (1) EP1206473B1 (is)
JP (1) JP4776842B2 (is)
KR (1) KR100756686B1 (is)
CN (1) CN1370173A (is)
AT (1) ATE280172T1 (is)
AU (1) AU776475C (is)
BG (1) BG65545B1 (is)
BR (1) BR0013811A (is)
CA (1) CA2381885C (is)
CZ (1) CZ2002616A3 (is)
DE (1) DE60015153T2 (is)
EA (1) EA005920B1 (is)
ES (1) ES2230140T3 (is)
HK (1) HK1046904B (is)
HU (1) HUP0202758A3 (is)
IL (2) IL148180A0 (is)
IS (1) IS2186B (is)
MX (1) MXPA02001789A (is)
NO (1) NO323375B1 (is)
NZ (1) NZ517174A (is)
PL (1) PL354180A1 (is)
PT (1) PT1206473E (is)
SK (1) SK286805B6 (is)
TR (1) TR200200474T2 (is)
WO (1) WO2001014380A1 (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
ES2307780T3 (es) * 2001-09-21 2008-12-01 Smithkline Beecham Corporation Compuestos quimicos.
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
ES2357948T3 (es) 2002-10-08 2011-05-04 Rinat Neuroscience Corp. Procedimientos para tratar dolor postquirúrgico mediante la administración de un anticuerpo frente al factor de crecimiento nervioso y composiciones que contienen el mismo.
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2005000194A2 (en) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
CA2511598C (en) * 2002-12-24 2016-09-13 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
PL379983A1 (pl) 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
DK2206728T3 (en) * 2004-04-07 2018-04-23 Rinat Neuroscience Corp METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
CA2580224A1 (en) * 2004-09-17 2006-03-30 Henry Ford Health System Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy
DK2383268T3 (en) 2005-02-04 2015-09-14 Astrazeneca Ab PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors
AU2006215386B2 (en) * 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
AU2006215394B2 (en) * 2005-02-16 2009-10-08 Astrazeneca Ab Chemical compounds
US20080287437A1 (en) * 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
TW200800963A (en) 2005-10-28 2008-01-01 Astrazeneca Ab Chemical compounds
KR20090004976A (ko) 2006-04-19 2009-01-12 아스테라스 세이야쿠 가부시키가이샤 아졸카르복사미드 유도체
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
US20090326229A1 (en) * 2006-08-02 2009-12-31 Takeda Phamaceutical Company Limited Alpha-carboline derivatives and methods for preparation thereof
WO2008058402A1 (en) * 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
WO2010131855A2 (ko) 2009-05-13 2010-11-18 덕산하이메탈(주) 오원자 헤테로고리를 포함하는 화합물 및 이를 이용한 유기전기소자, 그 단말
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ES2369596T3 (es) * 2007-05-04 2011-12-02 Astrazeneca Ab Derivados de amino-tiazolil-pirimidina y su uso para el tratamiento del cáncer.
EP2206707B1 (en) 2007-10-24 2014-07-23 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
WO2009088054A1 (ja) 2008-01-11 2009-07-16 Astellas Pharma Inc. 精巣の疼痛又は不快感行動及び頻尿併発モデル動物
KR20110017445A (ko) * 2008-06-11 2011-02-21 아스트라제네카 아베 암 및 골수증식성 장애의 치료에 유용한 트리시클릭 2,4-디아미노-ｌ,3,5-트리아진 유도체
TW201018693A (en) * 2008-09-30 2010-05-16 Astrazeneca Ab Chemical compounds 496-1p
WO2010059795A1 (en) 2008-11-19 2010-05-27 Cephalon, Inc. Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
US9233923B2 (en) 2009-03-30 2016-01-12 Duk San Neolux Co., Ltd. Organic compounds for organic electronic devices and terminals
EP3333188B1 (en) 2010-08-19 2022-02-09 Zoetis Belgium S.A. Anti-ngf antibodies and their use
KR101497122B1 (ko) * 2011-08-09 2015-03-06 덕산네오룩스 주식회사 2개 이상의 오원자 헤테로고리를 포함하는 화합물 및 이를 이용한 유기전기소자, 그 단말
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
ES2894852T3 (es) 2012-06-06 2022-02-16 Zoetis Services Llc Anticuerpos anti-NGF caninizados y métodos de los mismos
KR101478884B1 (ko) 2012-12-24 2015-01-05 충남대학교산학협력단 비스인돌일말레이미드계 화합물 및 이의 제조방법
KR20200090198A (ko) 2017-11-23 2020-07-28 바이오메드 엑스 게엠베하 트로포미오신 수용체 키나제 A(TrkA) 저해제로서의 피리미딘 유도체
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
FR2631199B1 (fr) 1988-05-09 1991-03-15 Centre Nat Rech Scient Reacteur a plasma
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
DE69409641T2 (de) 1993-05-28 1998-11-26 Cephalon, Inc., West Chester, Pa. Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
JP3998261B2 (ja) 1993-12-23 2007-10-24 イーライ・リリー・アンド・カンパニー プロテインキナーゼｃ阻害剤
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
GB9416467D0 (en) * 1994-08-13 1994-10-05 Wellcome Found Compounds for use in medicine
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
WO1997018809A1 (en) 1995-11-20 1997-05-29 Eli Lilly And Company Protein kinase c inhibitor
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
PT971717E (pt) 1996-08-22 2002-06-28 Bristol Myers Squibb Co Amino-acucar citotoxico e derivados de acucar afins de indolopirrolocarbazois
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones

Also Published As

Publication number Publication date
EA005920B1 (ru) 2005-08-25
US6635669B2 (en) 2003-10-21
AU776475C (en) 2005-04-07
KR100756686B1 (ko) 2007-09-07
NO323375B1 (no) 2007-04-16
SK286805B6 (sk) 2009-05-07
CA2381885C (en) 2009-10-27
JP4776842B2 (ja) 2011-09-21
HK1046904B (en) 2005-05-06
US6399780B1 (en) 2002-06-04
NO20020809L (no) 2002-02-20
NZ517174A (en) 2003-09-26
ES2230140T3 (es) 2005-05-01
US20020147341A1 (en) 2002-10-10
ATE280172T1 (de) 2004-11-15
CZ2002616A3 (cs) 2003-04-16
AU6647100A (en) 2001-03-19
EP1206473B1 (en) 2004-10-20
US6872746B2 (en) 2005-03-29
BG106423A (en) 2002-09-30
DE60015153D1 (de) 2004-11-25
US20050107458A1 (en) 2005-05-19
HK1046904A1 (en) 2003-01-30
PL354180A1 (en) 2003-12-29
JP2003507480A (ja) 2003-02-25
EA200200271A1 (ru) 2002-08-29
KR20020038730A (ko) 2002-05-23
TR200200474T2 (tr) 2002-06-21
MXPA02001789A (es) 2003-07-14
BR0013811A (pt) 2002-07-23
US20030216419A1 (en) 2003-11-20
IS6266A (is) 2002-02-12
CA2381885A1 (en) 2001-03-01
CN1370173A (zh) 2002-09-18
SK2462002A3 (en) 2002-12-03
PT1206473E (pt) 2005-01-31
EP1206473A1 (en) 2002-05-22
NO20020809D0 (no) 2002-02-19
DE60015153T2 (de) 2006-02-09
BG65545B1 (bg) 2008-11-28
AU776475B2 (en) 2004-09-09
IL148180A (en) 2008-04-13
WO2001014380A1 (en) 2001-03-01
HUP0202758A3 (en) 2004-12-28
US7291732B2 (en) 2007-11-06
HUP0202758A2 (hu) 2002-12-28
IL148180A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
IS6266A (is) Ísómerísk sambrædd pýrrólókarbazól og ísóindólón
MXPA02004415A (es) Pirazolonas sustituidas con heterociclicas.
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
HUP0203567A2 (hu) APRIL-receptor (BCMA) és alkalmazásai
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
ES2195163T3 (es) Derivados de pirimidina biciclicos y su uso como anticoagulantes.
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
EA200100887A1 (ru) Циклические замещенные конденсированные пирролкарбазолы и изоиндолоны
ATE274348T1 (de) Überbrückte indenopyrrolocarbazole
SG149045A1 (en) Novel fused pyrrolocarbazoles
TR200002380T2 (tr) Yeni triazolo (4,5-d) pirimidin bileşikleri
MY149041A (en) Novel fused pyrrolocarbazoles
YU62504A (sh) Triciklična 2-pirimidonska jedinjenja korisna kao inhibitori hiv reverzne transkriptoze
EE200200326A (et) Asendatud homopiperidüülbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
ES2195033T3 (es) Iso-indolonas condensadas utilizadas como inhibidores de proteina quinasa c.
EA199700223A1 (ru) Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции
EA200200981A1 (ru) Антагонисты рецептора il-8
ATE281455T1 (de) Oxindolderivate
ATE244714T1 (de) 1-(3-aminoindazol-5-yl)-3-phenylmethyl cyclische harnstoffe und ihre verwendung als hiv protease inhibitoren